Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia
暂无分享,去创建一个
R. Bociek | S. Joshi | Payal Gupta | A. Mittal | G. Hegde | Nagendra K. Chaturvedi | A. Joshi | Rae A. Rohlfsen
[1] P. Bierman,et al. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. , 2006, International journal of molecular medicine.
[2] A. Kristof,et al. Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. , 2008, Blood.
[3] C. Quilici,et al. CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn−/− Mice , 2009, The Journal of Immunology.
[4] Andreas Radbruch,et al. CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function , 2004, The Journal of experimental medicine.
[5] J. Leonard,et al. Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L , 2012, The Journal of Immunology.
[6] S. Fillatreau,et al. A New Role of CTLA-4 on B Cells in Thymus-Dependent Immune Responses In Vivo1 , 2007, The Journal of Immunology.
[7] E. Serfling,et al. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. , 1996, Leukemia & lymphoma.
[8] L. Rassenti,et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia , 2005, Leukemia.
[9] P. Linsley,et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. , 1997, Transplantation.
[10] G. Freeman,et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. , 1997, Journal of immunology.
[11] A. Lanfranco,et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.
[12] S. Malek,et al. Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.
[13] Susan O'Brien,et al. Chronic lymphocytic leukemia , 2011 .
[14] A. Sharpe,et al. CTLA‐4 regulates cell cycle progression during a primary immune response , 2002, European journal of immunology.
[15] L. Staudt,et al. Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs , 2004, BMC Immunology.
[16] A. Sheriff,et al. Lentiviral gene transfer of CTLA4 generates B cells with reduced costimulatory properties , 2009, Autoimmunity.
[17] I. Frydecka,et al. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients , 2005, Leukemia.
[18] A. Cross,et al. T cells are the main cell type expressing B7‐1 and B7‐2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis , 1999, European journal of immunology.
[19] H. Döhner,et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. , 2006, Blood.
[20] A. Rosenwald,et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. , 2009, Blood.
[21] D. Weisenburger,et al. Fluorescence in situ Hybridization Detection of Cytogenetic Abnormalities in B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2004, Leukemia & lymphoma.
[22] M. Rossi,et al. Poly(ADP-ribosyl)ation is implicated in the G0–G1 transition of resting cells , 2008, Oncogene.
[23] D. Weisenburger,et al. Hedgehog-Induced Survival of B-Cell Chronic Lymphocytic Leukemia Cells in a Stromal Cell Microenvironment: A Potential New Therapeutic Target , 2008, Molecular Cancer Research.
[24] Andrew W. Greaves,et al. Cyclic nucleotide phosphodiesterase 7B mRNA: An unfavorable characteristic in chronic lymphocytic leukemia , 2011, International journal of cancer.
[25] C. Croce,et al. Surface Expression of Bcl-2 in Chronic Lymphocytic Leukemia and Other B-Cell Leukemias and Lymphomas Without a Breakpoint t(14;18) , 2008, Molecular medicine.
[26] D. Spaner,et al. Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity1 , 2006, The Journal of Immunology.
[27] M. Pistillo,et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer , 2012, Cancer Immunology, Immunotherapy.
[28] J. Salisbury,et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. , 2008, Blood.
[29] Andrea Iaboni,et al. The interaction properties of costimulatory molecules revisited. , 2002, Immunity.
[30] S. Deaglio,et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. , 2005, Blood.
[31] T. Shanafelt,et al. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance , 2010, Leukemia.
[32] J. Briones,et al. Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia , 2005, Leukemia & lymphoma.
[33] R. Puri,et al. A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. , 2005, Leukemia research.
[34] J. Allison,et al. CTLA-4-Mediated inhibition of early events of T cell proliferation. , 1999, Journal of immunology.
[35] D. Weisenburger,et al. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. , 2007, International journal of molecular medicine.
[36] M. Mattei,et al. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. , 1991, Journal of immunology.
[37] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[38] A. García-Pardo,et al. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. , 2008, Blood.
[39] A. J. Wilson,et al. Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter1 , 2007, The Journal of Immunology.
[40] H. Wodrich,et al. Heterodimerization with Jun Family Members Regulates c-Fos Nucleocytoplasmic Traffic* , 2007, Journal of Biological Chemistry.
[41] J. Armitage,et al. ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia , 2007, Clinical Cancer Research.
[42] T. Dobosz,et al. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. , 2008, Human immunology.
[43] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[44] C. Thompson,et al. Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells , 2001, The Journal of experimental medicine.
[45] H. Reiser,et al. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] V. Boussiotis,et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. , 2008, Blood.
[47] Agustín Correa,et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. , 2010, Blood.
[48] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[49] N. Chiorazzi,et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. , 2007, Blood.
[50] Caleb B. McDonald,et al. Coupling of folding and DNA-binding in the bZIP domains of Jun-Fos heterodimeric transcription factor. , 2008, Archives of biochemistry and biophysics.
[51] J. Allison,et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[52] A. C. Ferrasi,et al. Relationship Between EBV Infection and Expression of Cellular Proteins c-Myc, Bcl-2, and Bax in Gastric Carcinomas , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[53] J. Dürig,et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia , 2002, Leukemia.
[54] D. Weisenburger,et al. Lymph node‐induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin‐1 , 2012, British journal of haematology.